President Trump announced a new initiative, TrumpRx.gov, a federal website where consumers will be able to purchase lower priced drugs. He also announced an agreement with Pfizer that would sell certain drugs at an average of 50% off list prices on the new platform. Pfizer’s deal with the Trump Administration exempts the company from pharmaceutical tariffs, so long as it agreed to invest in manufacturing in the U.S. 

The arrangement marks the Administration’s first direct-to-consumer agreement with a drugmaker and is expected to expand as additional pharmaceutical companies come on board. While pitched as a step toward “Most-Favored-Nation” pricing (which ensures Americans pay no more than patients abroad), key details remain unclear, including how discounts are calculated. The website is geared towards uninsured patients, meaning many patients may continue to pay less through their standard pharmacy benefits. 

The potential expansion of TrumpRx raises policy and operational considerations for health systems and pharmacies. If additional drugmakers join, the platform could draw uninsured patients toward direct government-facilitated purchases instead of traditional pharmacy channels while also potentially increasing access to more affordable drugs.